Molecular Sampling of Prostate Cancer: a dilemma for predicting disease progression

ABSTRACT: Current prostate cancer prognostic models are based on pre-treatment prostate-specific antigen (PSA) levels, biopsy Gleason score, and clinical staging but in practice are inadequate to accurately predict clinical disease progression. Hence, we sought to develop a molecular panel for prostate cancer progression by reasoning that molecular profiles might further improve current clinical models. We analyzed a Swedish Watchful Waiting cohort (1977–1999) with up to 30 years of clinical follow up using a novel method for gene expression profiling. This cDNA-mediated annealing, selection, ligation, and extension (DASL) method enabled the use of formalin-fixed paraffin-embedded transurethral resection of prostate (TURP) samples taken at the time of the initial diagnosis. We determined the expre

ORGANISM(S): Homo sapiens

SUBMITTER: Andrea Sboner 

PROVIDER: E-GEOD-16560 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress